JAK/HDAC-IN-4

JAK/HDAC-IN-4 (compound 11 i) is a JAK/HDAC inhibitor with the IC50 values of 0.49 nM and 12 nM for JAK2 and HDAC6, respectively. JAK/HDAC-IN-4 inhibits the cell proliferation and the production of nitric oxide. JAK/HDAC-IN-4 ameliorates psoriasis-like skin lesions in an Imiquimod (HY-B0180) -induced murine model with low toxicity[1].

Product Specifications

UNSPSC

12352005

Target

HDAC; JAK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/jak-hdac-in-4.html

Smiles

O=S(NC1=CC=C(C=C1)C2=NC(NC3=CC=C(C=C3)N4CCN(CC4)CC(NC5=CC=C(C=C5)C(NO)=O)=O)=NC=C2)(C)=O

Molecular Formula

C30H32N8O5S

Molecular Weight

616.69

References & Citations

[1]Hu W, et al. Discovery of Janus Kinase and Histone Deacetylase Dual Inhibitors as a New Strategy to Treat Psoriasis. J Med Chem. 2024 Nov 14;67 (21) :19267-19281.